CannabisRadio.com Launches New Podcast on Psychedelic Breakthrough Addiction Therapy

CannabisRadio.com, a leading podcast network previously focused on cannabis topics, has broadened its scope to include mental health, wellness, and longevity, introducing a new podcast titled 'Psychedelic Breakthrough Addiction Therapy.' Hosted by Deborah Mash, PhD, a renowned neuroscientist, the podcast aims to explore innovative treatments for addiction, with a particular focus on psychedelic medicines. The initiative underscores the growing interest in psychedelics as potential therapies for mental health disorders, despite their current legal status in many areas.

The podcast's inaugural series will concentrate on Ibogaine, a psychoactive compound from the Iboga plant, known for its potential in treating various addictions. Mash, with her extensive background in addiction neuroscience, brings invaluable insights into the discussion, highlighting the promise and challenges of psychedelic therapy. Her work, including the discovery of noribogaine, a metabolite of ibogaine, has paved the way for new treatments for alcohol and opioid use disorders.

Brandy Shapiro-Babin, President of CannabisRadio.com, emphasizes the network's commitment to providing accurate and reliable information to combat misinformation in the field. The podcast represents a significant step forward in educating the public about the therapeutic potential of psychedelics, offering hope to those affected by addiction.

Listeners can access 'Psychedelic Breakthrough Addiction Therapy' on various platforms, including Apple Podcasts, Spotify, and the CannabisRadio.com website. This expansion reflects CannabisRadio.com's dedication to covering emerging trends in plant medicine and psychedelics, catering to both experts and the curious alike.

DemeRx, Mash's clinical-stage biotech company, is at the forefront of developing non-addictive treatments for addiction, with ongoing research into noribogaine hydrochloride. The company's work exemplifies the potential of psychedelic-derived medicines to revolutionize addiction therapy, marking a pivotal moment in the intersection of neuroscience and psychedelic research.